key: cord-0828492-etj7jj36 authors: TYMS, A. STANLEY; TAYLOR, DEBRA L. title: Activity of glucosidase inhibitors against HIV infections date: 1988-09-03 journal: J Antimicrob Chemother DOI: 10.1093/jac/22.3.271 sha: 46cde61775b7c8c76fbaae07486485aebffda00a doc_id: 828492 cord_uid: etj7jj36 nan Most success to-date in the treatment of the Acquired Immunodeficiency Syndrome (AIDS) has been achieved with inhibitors of reverse transcriptase. The use of azidothymidine (AZT) has provided clinical benefits to patients with advanced disease and some clinical efficacy has been observed for a second nucleoside analogue, dideoxycytidine. Both drugs can induce serious side-effects with potential for long-term use being restricted, but other nucleoside derivatives are being investigated. Alternative targets for the chemotherapy of HIV infections are under consideration such as protease activity involved in the processing of viral proteins, anti-sense oligodeoxynudeotides to complement essential viral genes and post-translational events such as myristylation or glycosylation (subjects to be reviewed in the Journal's supplement on AIDS and related infections; Bint & Oxford, 1988) . In relation to the latter target, the antiviral properties of a series of polyhydroxyalkaloids against the growth of human immunodeficiency virus (HIV) in vitro have recently been described (Gruters et al., 1987; Tyms et al., 1987; Walker et at., 1987; A. Karpas, unpublished data) . These natural substances, which accumulate in plants and microorganisms but can also be synthesised, bear a structural resemblance to monosaccharides. Three different structural types are active, namely polyhydroxy derivatives of octahydroindolizine (castanospermine; CAST), piperidine (deoxynorimycin; DNJ) and pyrrolidine (dihydroxymethyldihydroxypyrrolidine; DMDP) (reviewed by Fellows, 1986) . These compounds are characterised by their ability to inhibit glucosidase activities involved in the trimming of the oligosaccharide side-chains of glycoproteins. The first step in the synthesis of iV-linked sugars in mammalian cells involves transfer of the glycan component of a lipidglycan intermediate to asparagjne residues on the nascent polypeptide chain. The initial structure of the branched glycan of TV-linked glycoproteins is .Af-acetylglucosamine 2 mannose 7-9 glucose 3. Subsequent modification involves the removal of the outermost glucose residue by glucosidase 1 (a 1,2 linkage) and the two remaining glucose residues by glucosidase 11 (lnm) which clearly correlated with an altered expression of viral giycoproteins on the virion surface (Taylor et al., 1988) . In this case, evidence points to the non-cleavage of a precursor glycoprotein when the glucose residues are retained on the glycan moiety. Similarly, a block in proteolytic cleavage of the Sindbis vims precursor E2 protein after treatment with methyl-DNJ accounted for the loss of extracellular virus (McDowell et al., 1987) and was consistent with earlier observations made with vesicular stomatitis virus (Schlesinger, Malfer & Schlesinger, 1984) and mouse hepatitis virus (Repp et al., 1985) . CAST, DNJ and DMDP were well tolerated in cell culture at concentrations with antiviral activity but only limited studies have been conducted on toxicity. The injection of young rats with CAST (up to 2000 mg/kg/ip) daily for three days induced diarrhoea suggestive of an inhibitory effect against gut glycosidases (Saul et al., 1985) . This was eliminated when animals were fed a simple diet based on glucose rather than complex carbohydrates although the inhibitory activity of 500 ings/kg on a-glucosidascs found in the liver and other organs was not reversed. In another study, the LD J0 for CAST in mice was also greater than 500 mg/kg (Sunkara et al., 1987) . Evidence for the non-toxic nature of polyhydroxyalkaloids in man was provided when derivatives of DNJ were used to control Type II diabetes (up to 200 mg/day orally for three days). The medication was well tolerated with no apparent side effects (Joubert, Bam & Manyane, 1986; Schnack et al., 1986) . Further information on toxicity and antiviral activity of glucosidase inhibitors in vivo should come from the study of retroviral infections in animal models. Treatment with either CAST or DNJ was recently shown to inhibit the growth in vitro of Moloney murine leukaemia virus (MoLV). In agreement with studies on HIV, neither of the mannosidase inhibitors, DMJ or swainsonine, showed antiviral activity against MoLV (Sunkara et al., 1987) . Enough is known about the antiviral activity of glucosidase inhibitors to warrant serious preclinical studies. Essential supplies of the natural compounds are scarce although synthetic substitutes may alleviate this problem. Derivatives of the presently available compounds are currently being investigated with the aim of identifying more potent agents with greater specificity for viral glycoprotein processing. Minor changes in the chemical structure of polyhydroxyalkaloids has already been shown to be important in influencing the antiviral activity (Tyms et al., 1987; Taylor et al., 1988) . Finally, if altering the oligosacchande structure of virion giycoproteins proves to be an effective antiviral strategy in AIDS, then it may be beneficial to use compounds in combination that have different target enzymes. AIDS related brain damage unexplained AIDS and AIDS-related infections: current strategies for prevention and therapy The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus The pyrroLdine alkaloid 2,5-dihydroxymethyl-3, 4-dihydroxypyrrotidine inhibits glycoprotein processing The biological activity of polyhydroxyalkaloids from plants Inhibitors of oligosacchande processing Biochenuca et Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase Effect of an alpha-glucosidase inhibitor (BAY m 1099) on postprandial blood glucose and insulin in type II diabetics Induction of CD4-dependent cell fusion by the HTLV HI/LAV envelope glycoprotein Glucose trimming and mannose trimming affect different phases of the maturation on Sindbis virus in infected BHK cells Carbohydrate abnormalities of AMinked plasma glycoproteins in liver disease Modification of HIV N-glycosylation by the a-mannosidase inhibitor swainsonine Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus Complete nucleotide sequence of the AIDS virus, HTLV-III The effects of processing inhibitors of N-linked oligosaccharides on the intracellular migration of glycoprotein E2 of mouse hepatitis virus and the maturation of coronavirus particles Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients Castanospermine inhibits aglucosidase activities and alters glycogen distribution in animals Inhibition of AMinked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases The formation of vesicular stomatitis virus (San Juan Strain) becomes temperature sensitive when glucose residues are retained on the oligosaccharides of the glycoprotein Effects of the a-glucosidase inhibitor 1 desoxynojirimycin (BAY m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients Role of the HTLV-111/LAV envelope in syncytium formation and cytopathicity Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoproteins synthesis Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine Acknowledgements. We wish to thank Dr Gary Jacob, University of Oxford, and Nicholas Alp, St. Bartholomew's Hospital Medical School, for their interest and comments.A. STANLEY TYMS*